Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia
Targacept, Inc. today announced positive top-line results from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.
Read more on
订阅：
博文评论 (Atom)
没有评论:
发表评论